Cancer and Immunotherapy Organizations Release Checkpoint Inhibitor Side Effect Guidelines

Elisa Becze BA, ELS, Editor


New guidelines and consensus recommendations for managing immune-related adverse events (irAEs) from checkpoint inhibitors are available from several key cancer and immunotherapy organizations: a collaboration between the American Society of Clinical Oncology and National Comprehensive Cancer Network, and a separate consensus recommendation from the Society for Immunotherapy of Cancer. ONS contributed to the developmentof both sets of guidelines.

View Article @

ONS Voice Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Voice Articles

Related Topics